Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2964-2970

  Degoey, David A ^a   Grampovnik, David J ^a   Flosi, William J ^a   Marsh, Kennan C ^a   Wang, Xiu C ^a   Klein, Larry L ^a   McDaniel, Keith F ^a   Liu, Yaya ^a   Long, Michelle A ^a   Kati, Warren M ^a   Molla, Akhteruzzaman ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; HISTAMINE; LOPINAVIR; LOPINAVIR OXYETHYLPHOSPHATE; LOPINAVIR OXYMETHYLPHOSPAHTE; PRODRUG; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR OXYBUTYLPHOSPHATE; RITONAVIR OXYETHYLPHOSPHATE; RITONAVIR OXYISOBUTYLPHOSPHATE; RITONAVIR OXYMETHYLPHOSPHATE; RITONAVIR PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DEPHOSPHORYLATION; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; PH; RAT;

ADMINISTRATION, ORAL; ANIMALS; DOGS; FEMALE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROGEN-ION CONCENTRATION; MALE; PRODRUGS; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RITONAVIR; SOLUBILITY; WATER;

EID: 65649149124     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900080g     Document Type: Article

References (17)

1. Recent reviews: (a) Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discovery 2008, 7, 255-270.
2. (b) Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404. (Pubitemid 38580074)
3. Chong, K.-T.; Ruwart, M. J.; Hinshaw, R. R.; Wilkinson, K. F.; Rush, B. D.; Yancey, M. F.; Strohbach, J. W.; Thaisrivongs, S. Peptidomimetic HIV protease inhibitor prodrugs with improved biological activities. J. Med. Chem. 1998, 36, 2575-2577.
4. Furfine, E. S.; Baker, C. T.; Hale, M. R.; Reynolds, D. J.; Salisbury, J. A.; Searle, A. D.; Studenberg, S. D.; Todd, D.; Tung, R. D.; Spaltenstein, A. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 2004, 48, 791-798. (Pubitemid 38280326)
5. Sohma, Y.; Hayashi, Y.; Ito, T.; Matsumoto, H.; Kimura, T.; Kiso, Y. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. J. Med. Chem. 2003, 46, 4124-4135. (Pubitemid 37122455)
6. Hamada, Y.; Matsumoto, H.; Yamaguchi, S.; Kimura, T.; Hayashi, Y.; Kiso, Y. Water-soluble prodrugs of dipetide HIV protease inhibitors based on O to N intramolecular acyl migration: design, synthesis and kinetic study. Bioorg. Med. Chem. 2004, 12, 159-170. (Pubitemid 38096228)
7. (a) Kempf, D. J.; Sham, H. L.; Marsh, K. C.; Flentge, C. A.; Betebenner, D.; Green, B. E.; McDonald, E.; Vasavanonda, S.; Saldivar, A.; Wideburg, N. E.; Kati, W. M.; Ruiz, L.; Zhao, C.; Fino, L.; Patterson, J.; Molla, A.; Plattner, J. J.; Norbeck, D. W. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 1998, 41, 602-617. (Pubitemid 28093094)
8. (b) Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C.-M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224. (Pubitemid 28553744)
9. For recent applications to other drugs classes, see the following: (a) Dhareshwar, S. S.; Stella, V. J. A Functional Group Approach to Prodrugs: Prodrugs of Alcohols and Phenols. In Prodrugs: Challenges and Rewards; Stella, V. J., Borchardt, R. T., Hageman, M. J., Oliyai, R., Maag, H., Tilley, J. W., Eds.; Springer Press/AAPS Press: New York, 2007; Part 2, pp 31-99.
10. (b) Fechner, J.; Schwilden, H.; Schüttler, J. Pharmacokinetics and Pharmacodynamics of GPI 15715 or Fospropofol (Aquavan Injection), a Water-Soluble Propofol Prodrug. In Modern Anesthetics; Schüttler, J., Schwilden, H., Eds.; Handbook of Experimental Pharmacology, Vol.182; Springer-Verlag: Berlin, 2008; pp 253-266.
11. (c) Garnier, T.; Mäntylä, A.; Järvinen, T.; Lawrence, J.; Brown, M.; Croft, S. In vitro studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother. 2007, 60, 802-810. (Pubitemid 47434259)
12. Golik, J.; Wong, H. S. L.; Chen, S. H.; Doyle, T. W.; Wright, J. J. K.; Knipe, J.; Rose, W. C.; Casazza, A. M.; Vyas, D. M. Synthesis and antitumor evaluation of paclitaxel phosphonooxymethyl ethers: a novel class of water soluble paclitaxel prodrugs. Bioorg. Med. Chem. Lett. 1996, 6, 1837-1842. (Pubitemid 26253887)
13. Available from Aldrich Chemical Company (Milwaukee, WI).
14. A report has recently appeared describing an OEP prodrug: Kumpulainen, H.; Järvinen, T.; Mannila, A.; Leppänen, J.; Nevalainen, T.; Mäntylä, A.; Vepsäläinen, J.; Rautio, J. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. Eur. J. Pharm. Sci. 2008, 34, 110-117.
15. Speit, G.; Schutz, P.; Merk, O. Induction and repair of formaldehyde-induced DNA-protein crosslinks in repair-deficient human cell lines. Mutagenesis 2000, 15, 85-90. (Pubitemid 30071765)
16. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of human immunodeficiency virus protease by coadministration of ritonavir. Antimicrob. Agents Chemother. 1997, 41, 654-660. (Pubitemid 27098420)
17. Law, D.; Schmitt, E. A.; Marsh, K. C.; Everitt, E. A.; Wang, W.; Fort, J. J.; Krill, S. L.; Qiu, Y. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 2004, 93, 563-570. (Pubitemid 38332289)